Orciprenaline

Orciprenaline

Orciprenaline
Systematic (IUPAC) name
(RS)-5-[1-hydroxy-2-(isopropylamino)ethyl]benzene-1,3-diol
Clinical data
AHFS/Drugs.com monograph
MedlinePlus
Pregnancy
category
  • AU: A
  • US: C (Risk not ruled out)
Legal status
Routes of
administration
Inhalation / tablets
Pharmacokinetic data
Bioavailability 3% if inhaled, 40% if taken orally
Metabolism Gastrointestinal and hepatic
Biological half-life 6 hours
Identifiers
CAS Registry Number  Y
ATC code R03 R03
R03
PubChem CID:
IUPHAR/BPS
DrugBank  N
ChemSpider  Y
UNII  Y
KEGG  Y
ChEBI  N
ChEMBL  Y
Chemical data
Formula C11H17NO3
Molecular mass 211.258 g/mol
Physical data
Solubility in water 9.7 mg/mL (20 °C)
 N   

Orciprenaline (INN), also known as metaproterenol (USAN), is a bronchodilator used in the treatment of asthma.[1][2] Orciprenaline is a moderately selective beta2-adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on alpha-adrenergic receptors. The pharmacologic effects of beta adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of ATP to cAMP. Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from many cells, especially from mast cells.

Possible side effects

  • tremor
  • nervousness
  • dizziness
  • weakness
  • headache
  • nausea
  • tachycardia
Rare side effects that could be life-threatening
  • increased difficulty breathing
  • rapid or increased heart rate
  • irregular heartbeat
  • chest pain or discomfort

Brand names

  • Alupent
  • Metaprel
  • Orcibest

References

  1. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). "DrugBank 3.0: a comprehensive resource for omics research on drugs". Nucleic Acids Res. 39 (Database issue): D1035–41.  
  2. ^ Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). "DrugBank: a knowledgebase for drugs, drug actions and drug targets". Nucleic Acids Res 36 (Database issue): D901–6.